Docetaxel

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg

Pieejams no:

REX Medical Ltd

SNN (starptautisko nepatentēto nosaukumu):

Docetaxel trihydrate 100.71 mg (equivalent to anhydrous docetaxel 80 mg)

Deva:

80 mg/mL

Zāļu forma:

Concentrate for infusion

Kompozīcija:

Active: Docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Vienības iepakojumā:

Vial, glass, Diluent, 6 mL

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

Cipla Ltd

Ārstēšanas norādes:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Produktu pārskats:

Package - Contents - Shelf Life: Vial, glass, Diluent - 6 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 80 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Autorizācija datums:

2006-06-23